Editas Medicine

At Editas Medicine, we are harnessing the potential of CRISPR gene editing to develop medicines for people living with serious diseases

[Editas Medicine @editasmed]

Editas successfully completed an up to $319.4M public offering. This milestone marks an exciting new chapter as we continue to advance EDIT-401 and drive towards our goal of delivering transformative medicines to people living with serious diseases. https://t.co/y9uKg1hBY3

[Editas Medicine @editasmed]

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference. For details, read the full press release here: https://t.co/wiaY9ayRYt.

#JefferiesHealthcare #cardiovasculardisease #biotech #invivo

[Editas Medicine @editasmed]

At #EASCongress2026 earlier this week, we presented new preclinical data supporting the continued advancement of our lead in vivo development candidate, EDIT-401. View the press release here: https://t.co/dGc8LSVAK2. #invivo #geneediting #cardiovasculardisease

[Editas Medicine @editasmed]

#NEWS: Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress. Read the press release here: https://t.co/q63tIcEawB. #EASCongress2026 #invivo

[Editas Medicine @editasmed]

We’re excited to attend the 94th European Atherosclerosis Society Congress in Athens next week, where we’ll present new preclinical data on our lead in vivo development candidate, EDIT-401. For more details, read here: https://t.co/LzFanKHZlu.
#EASCongress2026 #invivo

[Editas Medicine @editasmed]

It was a pleasure to participate in #ASGCT2026 and #TIDESUSA last week, where we were excited to share new preclinical data for our lead in vivo development candidate, EDIT-401. Thank you to everyone who spent time with the Editas team!
#invivo #cardiovasculardisease #biotech

[Editas Medicine @editasmed]

This week at #ASGCT2026, we presented new preclinical data supporting the continued advancement of our lead in vivo development candidate, EDIT-401, as well as the broader potential of our differentiated upregulation strategy. View the presentations here: https://t.co/WXF4dqeiqh.

[Editas Medicine @editasmed]

Join us today as we present new preclinical data from our lead in vivo development candidate, EDIT-401, in an oral presentation at #ASGCT2026. #invivogeneediting #cardiovasculardisease #biotechnology

[Editas Medicine @editasmed]

#NEWS: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting. Read the press release for details: https://t.co/NLPRJsYvdP.
#ASGCT2026 #invivo

[Editas Medicine @editasmed]

Today we’re at the TIDES USA 2026 Meeting, where we’ll be sharing more information on our lead in vivo development candidate, EDIT-401, in an oral presentation. For details, visit the TIDES website: https://t.co/OlwmzmmwWu. #TIDESUSA #invivo #geneediting #cardiovasculardisease

[Editas Medicine @editasmed]

Attending ASGCT? Check out our posters featured during the Wednesday and Thursday Poster Receptions from 5:00 p.m. – 6:30 p.m. EDT in the Exhibit and Poster Hall. For more information on the presentations, read here: https://t.co/LzFanKHZlu.

#ASGCT2026 #geneediting #healthcare

[Editas Medicine @editasmed]

This week, we’ll be presenting new preclinical data at the American Society of Gene and Cell Therapy and TIDES USA annual meetings. For more details on our presence at each conference, read here: https://t.co/LzFanKHZlu. #ASGCT2026 #TIDESUSA #invivo #cardiovasculardisease

[Editas Medicine @editasmed]

Yesterday, Editas Medicine announced first quarter 2026 results and business updates. Read the full press release here: https://t.co/QBfVWOo8na.

#geneediting #biotech #cardiovasculardisease #hyperlipidemia

[Editas Medicine @editasmed]

#NEWS: Editas Medicine Announces First Quarter 2026 Results and Business Updates. For more details, read the full press release here: https://t.co/QBfVWOo8na #invivo #cardiovasculardisease #geneediting #earnings

[Editas Medicine @editasmed]

#NEWS: Editas Medicine to Present New Preclinical Data at Upcoming Scientific Conferences. For more details, read the full press release here: https://t.co/5WSWqq4Vzw #invivo #geneediting #cardiovascular #ASGCT2026 #TIDESUSA #EASCongress2026

[Editas Medicine @editasmed]

Editas presented at the 5th Lipid Nanoparticle Formulation & Process Development Summit, sharing insights on consistent, scalable LNP manufacturing through optimized mixing processes. We're proud to contribute to conversations shaping the future of gene editing. #geneediting #LNP

[Editas Medicine @editasmed]

#News: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference. Read the full press release here: https://t.co/qbq3wtMAg7 #invivogeneediting #biotechnology #CRISPR

[Editas Medicine @editasmed]

#NEWS: Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates. For more details, read the full press release here: https://t.co/HdL9bLUQ9z #biotech #geneediting #earnings

[Editas Medicine @editasmed]

#News: Editas Medicine to Participate in Upcoming Investor Conferences. For more details, read the full press release here: https://t.co/dbV9F6xS9M #invivogeneediting #biotechnology #healthcare

[Editas Medicine @editasmed]

Gilmore O’Neill joined the Let's Talk About That podcast to discuss the future of in vivo gene editing and EDIT-401, an experimental, potential best-in-class, one-time therapy that has achieved ≥90% mean LDL cholesterol reduction in NHPs. Listen here: https://t.co/mMmGjjrG8F